Oncology Market In China Outpaces Pharma Industry; Targeted Therapies Enjoy Fastest Growth - Citi Research
This article was originally published in The Pink Sheet Daily
Executive Summary
Three national surveys revealed that lung, liver, stomach and esophageal cancer were the top four killers in the last 30 years, accounting for roughly 70% of deaths from cancer in China.
You may also be interested in...
Insider Analysis From Easton Associates: Are Patient Assistance Programs The Silver Bullet To Meet Affordability Challenges In China?
By Celia Deng, Zhiyi Tong and Paul Zhang
Will China's Enlarged Medical Insurance System Cover More Oncology Treatments?
SHANGHAI - Although China's pharmaceutical market slowed down in the first quarter of 2011 due to price cuts and policy headwinds, it still grew at 14.5% compared to the same period last year, according to data from investment brokerage Citi. Growth largely was driven by increasing medical expenses in the world second largest economy, and in particular was fueled by China's second and third-tier cities, away from the coast, which saw first quarter prescription drug growth rates between 20-30% year over year
China's Simcere Reports Slow Q1 Results, But Sales Force Reorganization Could Help Attract New Pharma Partners
SHANGHAI - Simcere Pharmaceutical Group, one of the first Chinese domestic pharmaceutical companies to list in the U.S., reported a slow first quarter result due to slower than expected sales of lead product line first-to-market edavarone injection branded Bicun and Yidasheng.